{"eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":28,"description":"Patients received daratumumab 16 mg/kg IV over 1.5 hours. Treatment continues in the absence of disease progression or unacceptable toxicity.","id":"EG000","otherNumAffected":0,"otherNumAtRisk":28,"seriousNumAffected":0,"seriousNumAtRisk":28,"title":"Treatment (Daratumumab)"}],"frequencyThreshold":"5","timeFrame":"Adverse events were collected at the day of infusion"}